An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone online asked whether people who take GLP‑1 drugs (the class that includes medicines like Ozempic and Wegovy) notice a lasting drop in compulsive or addictive behaviors — not just less appetite, but things like doom‑scrolling, bingeing, drinking, or other impulsive habits. The question came from someone two weeks into treatment who already felt a quieter, less reward‑seeking state and wondered if that persists long term. GLP‑1s are a type of medicine that mimic a natural hormone made in the gut. People mostly know them for lowering appetite and helping with weight loss or blood‑sugar control. In plain terms, they change how the body and brain respond to signals about hunger and reward. They don’t directly “cure” addiction, but because they alter reward pathways and feelings of craving, researchers and patients have noticed effects beyond eating. What studies actually show is mixed and mostly early. Some animal studies and small human reports suggest GLP‑1 drugs can reduce seeking behaviors for things like food, alcohol, and nicotine. But most robust evidence is about appetite and metabolic outcomes; the research on compulsive behaviors in people is limited, often small, short‑term, or observational (meaning people report changes but there aren’t large controlled trials). So early changes after a couple of weeks — like feeling less driven to binge or scroll — are believable, but we don’t yet have strong proof about how common or long‑lasting that effect is for everyone. Why it matters is straightforward: if these drugs do reduce compulsive reward‑seeking, they could help people who struggle with multiple kinds of addictive behaviors, not just overeating. That could change how clinicians think about treating overlapping problems like obesity and substance use. For an individual, it might mean fewer urges and an easier time breaking bad habits while on the medication. But it’s not a magic fix for underlying issues that often need therapy, lifestyle changes, or addiction‑specific treatment. There are important caveats. GLP‑1s have side effects — nausea, stomach upset, possible gallbladder or pancreas concerns — and long‑term safety questions remain under study for some uses. They’re prescription medicines, not over‑the‑counter habit suppressors. People with certain medical conditions or on specific medications shouldn’t use them without a doctor. Also, just because someone reports feeling “less compulsive” doesn’t prove the drug cured the underlying behavior; placebo effects, changes in routine, or added support (diet counseling, therapy) can also help. Finally, regulators have approved these drugs for metabolic conditions; using them specifically to treat addiction is still experimental. Bottom line: some people do report a quieter, less compulsive mind on GLP‑1s, and early research hints this is real, but we don’t yet know how common or lasting that effect is or who benefits most.
Source: r/Mounjaro